NCT01382745View on ClinicalTrials.gov

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2021

Study Completion Date

January 31, 2022

Conditions
Squamous Cell Carcinoma of Anal Canal
Interventions
DRUG

Nimotuzumab

200mg Nimotuzumab once a week for 12 weeks

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

YM BioSciences
All Listed Sponsors
collaborator

YM BioSciences

INDUSTRY

lead

Dr. Te Vuong

OTHER

NCT01382745 - Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers | Biotech Hunter | Biotech Hunter